TCGA-D8-A1XR-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 16
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.410
- DNA_REPAIR+0.210
- MITOTIC_SPINDLE+0.180
- E2F_TARGETS+0.170
- G2M_CHECKPOINT+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.120
- NOTCH_SIGNALING+0.090
- ANDROGEN_RESPONSE+0.080
- ESTROGEN_RESPONSE_EARLY+0.050
- HEDGEHOG_SIGNALING+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.380
- COMPLEMENT-0.360
- APICAL_JUNCTION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.330
- IL2_STAT5_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A3IZ-01A-11R-A213-07 | — | B | 0.902 |
| 2 | SRR9879267 | — | cohortA1 | 0.893 |
| 3 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.882 |
| 4 | ERR2598236 | fetal | fetal | 0.877 |
| 5 | MDT-AP-0113 | Med | Medulloblastoma | 0.873 |
| 6 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.865 |
| 7 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.860 |
| 8 | SRR662871 | GTEX | — | 0.859 |
| 9 | MDT-AP-3021 | Med | Medulloblastoma | 0.859 |
| 10 | TCGA-DK-AA76-01A-11R-A39I-07 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.410 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |